Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Resected Stage IB-IIIA NSCLC
NCT02486718Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2015
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Oct 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02486718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486718.